Another combination regimen, using encorafenib, cetuximab, and an ERK1/2 selective inhibitor, ulixertinib, led to significant tumor regression in the BRAF V600E-mutant CRC model in preclinical studies. This evidence concerns the gene BRAF and neoplasm.